Showing results (2521-2530 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 15, 2015
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinomaSadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
Investigational New Drugs|February 14, 2016
Targeted therapies in gastric cancer treatment: where we are and where we are goingGianluca Tomasello, Michele Ghidini, Wanda Liguigli, et al.
Investigational New Drugs|August 28, 2015
Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosisTessa Tabouret, Thomas Gregory, Marion Dhooge, et al.
Investigational New Drugs|August 20, 2015
BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatmentSvetlana A Protsenko, Anna I Semionova, Yuri I Komarov, et al.
Investigational New Drugs|January 20, 2015
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrationsTrevor J Mathias, Karthika Natarajan, Suneet Shukla, et al.
Investigational New Drugs|November 1, 1989
Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell linesP B Jensen, H Roed, L Vindeløv, et al.
Investigational New Drugs|October 25, 2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancerBo Mi Ku, Eun Hye Jho, Yeon-Hee Bae, et al.
Investigational New Drugs|December 16, 2014
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumorsYasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
Pageof 372